Schaeffer Center for Health Policy & Economics

Value of Life Sciences Innovation

Research Program

Value of Life Sciences Innovation

Biomedical advances are at the front lines of transforming healthcare through innovations that benefit countless people. The Value of Life Sciences Innovation (VLSI) program exemplifies the Schaeffer Center’s focus on evidence-based analyses that encourage breakthroughs while developing pricing and reimbursement strategies to help ensure that patients receive the therapies they need.

Program Leadership

Alice Chen, PhD

Senior Scholar, USC Schaeffer Institute
Director, Value of Life Sciences Innovation
Associate Professor and Vice Dean for Resarch, USC Price School of Public Policy
2018-2019 RCMAR Scientist, USC Schaeffer Center

Desi Peneva, MS

Associate Director, Value of Life Sciences Innovation
Research Program Lead, USC Schaeffer Center

Dana Goldman, PhD

Founding Director, USC Schaeffer Institute for Public Policy & Government Service
University Professor of Public Policy, Pharmacy, and Economics
Special Advisor, USC Provost

Spotlight on PBMs View All

Testimony on Competition Issues in the Prescription Drug Supply Chain

Implementing reforms that increase transparency, align incentives and restore competition can ensure that PBMs fulfill their intended role: helping to make prescription drugs more affordable and accessible for all Americans.

Healthcare Markets

Experts: Neeraj Sood

Pharmacies Excluded from Preferred Networks Face Much Higher Risk of Closure

Medicare Beneficiaries Face Much Higher Drug Costs as Plans Quickly Shift to Coinsurance

How the Secrecy of Middlemen Inflates Drug Prices

Featured Perspective

Ensuring Most-Favored Nation Drug Pricing Doesn’t Sicken Us

Lowering drug prices to European benchmarks would ultimately reduce innovation and make Americans less healthy. Instead, a drug pricing system based on U.S. values would enhance access and support medical progress.

Experts: Darius Lakdawalla, Dana Goldman

Read: Ensuring Most-Favored Nation Drug Pricing Doesn’t Sicken Us

Latest Research View All

Perspective

Benchmarking Drug Prices To Inflation Overlooks What Truly Matters: Value

Holding pharmaceutical innovation to the same metric we use for breakfast cereal is not fiscal prudence, it’s conceptual confusion.

Featured Experts: William Padula

Testimony

Testimony on Accelerating Medical Breakthroughs for American Patients and Their Families

Evidence Base

The Value of Earlier Initiation of Anti-Amyloid Therapy for Alzheimer’s Disease

Perspective

Assessing the Case Against Direct-to-Consumer Drug Advertisements

In The News View All

Associated Press

Padula comments on the difficulty of assessing the potential effects of the White House’s drug pricing deals

Featured Experts: William Padula

Medscape

Peters interviewed about how new GLP-1 guidelines and price reductions will affect patients

Featured Experts: Anne Peters

Modern Healthcare

Sood explains how newer, alternative PBMs often have business with legacy firms

Featured Experts: Neeraj Sood

Axios

Schiller discusses opportunities to strengthen U.S. competitiveness in early-phase clinical research

Featured Experts: Lowell Schiller

KFF

Lakdawalla discusses recent developments in drug pricing policy on KFF webinar

Featured Experts: Darius Lakdawalla

Related Center

Clinical Trial Recruitment Lab (CTRL)

We’re bringing together stakeholders from academia, industry, and philanthropy to test and disseminate innovative recruitment strategies that improve access and representation in clinical trials.

Learn More